Litigation in paediatric urology within the National Health Service (NHS) England: an analysis of costs and causes - Scorecard - MDSpire

Litigation in paediatric urology within the National Health Service (NHS) England: an analysis of costs and causes

  • By

  • Panagiotis Nikolinakos

  • Katie McComb

  • Marina Maria Antonaraki

  • Ivo Donkov

  • Nadir I. Osman

  • Karl H. Pang

  • March 28, 2026

  • 0 min

Share

Clinical Scorecard: Analysis of Legal Claims in Pediatric Urology within NHS England: Examining Costs and Contributing Factors

At a Glance

CategoryDetail
ConditionPediatric urological conditions requiring surgical or clinical intervention
Key MechanismsClinical decision-making errors including failure or delay in diagnosis and treatment, inappropriate treatment, and follow-up failures
Target PopulationPatients under 18 years receiving urological care within NHS England
Care SettingNHS hospitals and clinical settings providing pediatric urology services

Key Highlights

  • From 2006/2007 to 2024/2025, 216 pediatric urology litigation claims were notified, with 62% successful.
  • Total financial burden for successful claims was £10.23 million over 19 years, averaging £76,000 per claim.
  • Leading causes of successful claims included failure or delay in diagnosis (29.1%) and failure or delay in treatment (24.6%).

Guideline-Based Recommendations

Diagnosis

  • Ensure timely and accurate diagnosis to reduce failure or delay-related claims.

Management

  • Avoid inappropriate treatment and delays in performing operations through adherence to clinical protocols.
  • Organize and document follow-up arrangements effectively to prevent related litigation.

Monitoring & Follow-up

  • Monitor trends in litigation claims to identify areas for clinical improvement and risk reduction.

Risks

  • Recognize that failure or delay in diagnosis and treatment are primary contributors to litigation risk in pediatric urology.

Patient & Prescribing Data

Pediatric patients (<18 years) receiving urological care within NHS England

Data do not specify treatment types; however, litigation is associated with treatment delays, inappropriate interventions, and follow-up failures.

Clinical Best Practices

  • Maintain vigilance for early diagnosis and prompt treatment initiation in pediatric urology cases.
  • Implement robust follow-up systems to ensure continuity of care.
  • Engage in multidisciplinary collaboration to reduce clinical errors and litigation risk.
  • Utilize litigation data insights to inform quality improvement initiatives.

References

Original Source(s)

Litigation in paediatric urology within the National Health Service (NHS) England: an analysis of costs and causes

  • by Panagiotis Nikolinakos, Katie McComb, Marina Maria Antonaraki, Ivo Donkov, Nadir I. Osman, Karl H. Pang

  • March 28, 2026

Related Content

Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

  • by

  • April 15, 2026

  • 22 min